Michael Huang Net Worth

Michael Huang biography

Michael Huang serves as Independent Director of the Company. Mr. Huang serves as Managing Partner at Taiwania Capital Management Corporation, a venture capital firm. From 2014 to 2017, Mr. Huang served as Chief Executive Officer of NeuroVive Pharmaceutical Asia, Inc., a biopharmaceutical company. Mr. Huang holds an MBA from Rice University, a M.A. in Chemistry from the University of Texas, Arlington, and a B.S. from University of Texas, Austin.

What is the salary of Michael Huang?

As the Independent Director of Frequency Therapeutics Inc, the total compensation of Michael Huang at Frequency Therapeutics Inc is $94,463. There are 9 executives at Frequency Therapeutics Inc getting paid more, with David Lucchino having the highest compensation of $7,364,600.

How old is Michael Huang?

Michael Huang is 46, he's been the Independent Director of Frequency Therapeutics Inc since 2018. There are 15 older and 2 younger executives at Frequency Therapeutics Inc. The oldest executive at Frequency Therapeutics Inc is Timothy Barberich, 72, who is the Independent Director.

What's Michael Huang's mailing address?

Michael's mailing address filed with the SEC is C/O FREQUENCY THERAPEUTICS, INC.,, 75 HAYDEN AVE, SUITE 300, LEXINGTON, MA, 02421.

Insiders trading at Frequency Therapeutics Inc

Over the last 5 years, insiders at Frequency Therapeutics Inc have traded over $11,017,122 worth of Frequency Therapeutics Inc stock and bought 369,233 units worth $5,339,982 . The most active insiders traders include Joel S Marcus, Robert Langer a Marc A Cohen. On average, Frequency Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,858. The most recent stock trade was executed by Richard J. Mitrano on 18 August 2023, trading 464 units of FREQ stock currently worth $269.

What does Frequency Therapeutics Inc do?

frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.

Frequency Therapeutics Inc executives and stock owners

Frequency Therapeutics Inc executives and other stock owners filed with the SEC include:

• David Lucchino,
  President, Chief Executive Officer, Co-Founder, Director
• Christopher Loose,
  Co-Founder, Chief Scientific Officer
• Carl LeBel,
  Chief Development Officer
• David L. Lucchino,
  Co-Founder, Pres, CEO & Director
• Wendy S. Arnold,
  Chief People Officer
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Robert Langer,
  Independent Director
• Marc Cohen,
  Lead Independent Chairman of the Board Director
• Joel Marcus,
  Independent Director
• Michael Huang,
  Independent Director
• Timothy Barberich,
  Independent Director
• Carlo Tanzi,
  IR Contact Officer
• Cynthia Feldmann,
  Independent Director
• Dana Hilt,
  Chief Medical Officer
• Ajay Rai,
  Vice President - Business Development
• Richard Mitrano,
  Vice President of Finance and Operations
• Wendy Arnold,
  Chief People Officer
• William Mclean,
  Co-Founder, Vice President - Biology and Regenerative Medicine
• Dr. Carl P. LeBel,
  Chief Devel. Officer
• Dr. Christopher R. Loose,
  Co­-Founder & Chief Scientific Officer
• Dr. William W. Chin M.D.,
  Sr. VP of Translational Medicine
• Dr. Dana C. Hilt,
  Chief Medical Officer
• Dr. Jeff Hrkach,
  Sr. VP of Technology Devel.
• Richard J. Mitrano,
  VP of Fin. & Operations
• William J. McLean Ph.D.,
  Co-founder & Sr. VP of Hearing Biology and Translational Research
• Quentin Mc Cubbin,
  Chief Manufacturing Officer
• James E Deerfield Mgmt L.P....,
  
• Peter P. Pfreundschuh,
  Chief Financial Officer
• Michael Bookman,
  General Counsel and Secretary